The federal authorities has moved to cease any additional danger of contamination at a Baltimore contract vaccine producer the place 15 million potential doses of Johnson & Johnson vaccine had been spoiled final month, telling rival drugmaker AstraZeneca it should transfer its manufacturing from the plant and discover elsewhere to make its vaccine.
The Emergent BioSolutions plant in Baltimore was making coronavirus vaccines below contract to each Johnson & Johnson and AstraZeneca. Final month, a batch of Johnson & Johnson “drug product” failed quality control and was taken out of manufacturing, each J&J and Emergent have mentioned.
The federal authorities has directed Johnson & Johnson to completely take over its vaccine manufacturing on the plant, an administration official informed CNN Saturday. The corporate confirmed it was taking tighter management of the manufacturing course of.
The Emergent BioSolutions plant, which had been making doses of each Johnson & Johnson’s vaccine in addition to a vaccine made for AstraZeneca, will now solely produce J&J vaccines, the official mentioned. The Well being and Human Companies Division has directed that the AstraZeneca vaccine will now be produced at one other plant, though the official didn’t specify the place.
“Johnson & Johnson is assuming full duty relating to the manufacturing of drug substance for its COVID-19 vaccine on the Emergent BioSolutions Inc. Bayview facility,” the corporate mentioned in a press release emailed to CNN.